
    
      The primary objective of the study is to demonstrate that the efficacy of OCTAPLEX as a
      reversal agent in patients under Vitami n K Antagonist (VKA)therapy with the need for urgent
      surgery with significant bleeding risk is clinically non-inferior to that Beriplex® P/N
      (Kcentra).

      The secondary objective of the study is to investigate the safety and tolerability of
      OCTAPLEX compared to Beriplex® P/N (Kcentra) in patients under Vitamin K Antagonist (VKA)
      therapy with the need for urgent surgery with significant bleeding risk.
    
  